Trends in the epidemiology and prescribing of medication for allergic rhinitis in England.

Ayr Hospital, UK.
Journal of the Royal Society of Medicine (Impact Factor: 2.02). 09/2008; 101(9):466-72. DOI: 10.1258/jrsm.2008.080096
Source: PubMed

ABSTRACT To investigate recent trends in the recorded incidence, lifetime prevalence and prescribing of symptom relief medication for allergic rhinitis in England.
Analysis of primary healthcare datasets.
The UK prevalence of allergic rhinitis has increased very significantly over recent decades. Analysis of primary healthcare datasets offers the possibility to advance understanding about the changing epidemiology and management of allergic rhinitis. QRESEARCH is one of the world's largest national aggregated health databases containing the records of over nine million patients. We extracted data on all patients with a recorded diagnosis of allergic rhinitis and calculated annual age-sex standardized incidence and lifetime period prevalence rates for each year from 2001-2005. We also analysed prescribing trends for antihistamines and drugs used in nasal allergy in those with a recorded diagnosis of allergic rhinitis.
Age-sex standardized incidence, lifetime prevalence rates and prescribing trends for symptom relief medication for allergic rhinitis in England.
The age-sex standardized incidence of allergic rhinitis was 5.57 per 1000 person-years in 2001 and increased by 33.0% to 7.41 per 1000 person-years in 2005 (P<0.001). Lifetime age-sex standardized prevalence of a recorded diagnosis of allergic rhinitis increased by 43.2% from 46.35 per 1000 in 2001 to 66.37 per 1000 in 2005 (P<0.001). Over this period a 41.7% overall increase in prescriptions for antihistamines and drugs used in nasal allergy was observed (antihistamines 45.5%, drugs used in nasal allergies 35.5%).
Recorded incidence and lifetime prevalence of allergic rhinitis have increased substantially in recent years. A similar increase in prescriptions for antihistamines and drugs used in nasal allergy in patients with allergic rhinitis is also observed.

  • BMJ Clinical Research 07/2014; 349:g4153. DOI:10.1136/bmj.g4153 · 14.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The SNOT-20 questionnaire, a valid disease related quality of life instrument for rhinosinusitis, was modified for use in secondary school children and became the Modified Sino Nasal Outcome Test -20 Young Person Questionnaire, MSYPQ. Methododology: MSYPQ was evaluated in a pilot study of disease (rhinosinusitis) and non-disease according to criteria in the European Position Paper on Rhinosinusitis and Nasal polyposis (EPOS). Results: Those children who were suffering from rhinosinusitis according to the EPOS criteria showed significantly high scores on MSYPQ, whereas those who did not have rhinosinusitis had very low to zero scores on the MSYPQ. Conclusion: This pilot study confirmed that the MSYPQ recognises rhinosinusitis symptoms in the 11-16 year age group with its effect on quality of life and is a suitable instrument to investigate the prevalence and impact of this problem in young people.
    Rhinology 09/2014; Rhinology(52):215-224. DOI:10.4193/Rhino12.011-2 · 2.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Few time-series studies, and none lasting longer than 4 years, have investigated the aetiology of treated seasonal allergic rhinoconjunctivitis (SAR) on the basis of anti-allergic medication prescriptions. The aim of the present paper was to study the short-term relationship between pollen exposure and drug-treated SAR over 10 years in an urban area in central France.MethodsA SAR case was defined as the association of an oral antihistamine and a local antiallergic drug on the same prescription. The relationship between daily changes in pollen concentrations and daily changes in the number of treated SAR cases was analyzed using generalized additive models, taking into account confounding factors such as air pollution, weather and days of the week.ResultsBetween 2003 and 2012, the total yearly number of treated SAR cases rose from 7,265 to 11,315. The relative risk of treated SAR associated with an interquartile increase in pollen concentration increased significantly for Fraxinus, Betula, Carpinus, Platanus, Poaceae and Urticaceae for the whole pollen season, and for Urticaceae in the first semester.Conclusions The prevalence of treated SAR cases rose by about 55% in 10 years. The study confirmed the highly allergenic role of Fraxinus, Betula and Poaceae pollens but also showed a relatively unknown association between treated SAR and Carpinus and Platanus pollens, despite theirpollen counts being less than 1% of overall pollen concentration. It also showed robust correlations with Urticaceae pollens, especially during the first semester, suggesting a potential allergenic role of Parietaria pollination in this non-Mediterranean area.This article is protected by copyright. All rights reserved.
    Allergy 09/2014; DOI:10.1111/all.12522 · 6.00 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014